Official reprint from UpToDate®
www.uptodate.com ©2018 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Use of intracoronary stents for specific coronary lesions

Donald Cutlip, MD
Section Editor
Stephan Windecker, MD
Deputy Editor
Gordon M Saperia, MD, FACC


Percutaneous coronary intervention (PCI) refers to both non-stenting procedures and stent interventions. Stenting represented an advance over percutaneous transluminal coronary angioplasty (PTCA) alone because acute procedural success was higher and the rate of restenosis requiring target lesion revascularization was much lower. Approximately 20 to 30 percent of patients required clinically-driven repeat target lesion revascularization within the first year after PTCA alone compared to 10 to 15 percent with bare-metal stents [1-3].

Drug-eluting stents (DES) represented a further advance in PCI and are now used in the majority of procedures. In addition, newer generation DES are used in preference to first generation DES. (See "Drug-eluting intracoronary stents: General principles", section on 'Efficacy and safety compared to BMS' and "Comparison of drug-eluting intracoronary stents", section on 'Comparison of all DES'.)

The use of PCI for specific coronary lesions will be reviewed here. The emphasis will be on the outcomes with DES. Issues related to the use of DES, the major clinical trials demonstrating the efficacy of DES compared to bare-metal stents, and the general principles of stent deployment are discussed separately. (See "Drug-eluting intracoronary stents: General principles" and "Clinical use of intracoronary bare metal stents" and "General principles of the use of intracoronary stents".)


The 2007 American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions focused update for percutaneous coronary intervention recommended use of a drug-eluting stent (DES) as an alternative to bare-metal stents in patients with lesions for which a favorable efficacy and safety profile has been demonstrated in clinical trials [4]. Use of a DES with other lesions could be considered but the efficacy was less well established.

Patients with DES may require more prolonged dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker because of a possible increased risk of late stent thrombosis, especially if therapy is interrupted for noncardiac surgery. As a result, a bare-metal stent or balloon angioplasty was recommended for those patients in whom surgical or invasive procedures were likely in the 12 months following DES implantation. The importance of antiplatelet therapy to prevent stent thrombosis, updated guideline recommendations, and recommended regimens with the different types of stents are discussed separately. (See "Coronary artery stent thrombosis: Incidence and risk factors" and "Long-term antiplatelet therapy after coronary artery stenting in stable patients" and "Antithrombotic therapy for elective percutaneous coronary intervention: General use".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Dec 2017. | This topic last updated: Aug 24, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2018 UpToDate, Inc.
  1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.
  2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.
  3. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40:2082.
  4. King, SB, Smith, SC, Hirshfeld, JW Jr, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for PCI. Circulation 2008; 117:e1. Available at: http://circ.ahajournals.org (accessed January 29, 2008).
  5. Klein LW. Are drug-eluting stents the preferred treatment for multivessel coronary artery disease? J Am Coll Cardiol 2006; 47:22.
  6. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.
  7. Macaya C, Garcia H, Serruys P, et al. Sirolimus-eluting stents versus surgery and bare metal stenting in the treatment of diabetic patients with multivessel disease—a comparison between ARTS I and ARTS II (abstract). Circulation 2005; 112:II.
  8. Glaser R, Selzer F, Faxon DP, et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005; 111:143.
  9. Mehta RH, Lopes RD, Ballotta A, et al. Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? Am Heart J 2010; 159:141.
  10. Hannan EL, Racz M, Holmes DR, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 2006; 113:2406.
  11. Hannan EL, Wu C, Walford G, et al. Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. JACC Cardiovasc Interv 2009; 2:17.
  12. van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 2002; 39:559.
  13. Kim YH, Park DW, Lee JY, et al. Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. Circulation 2011; 123:2373.
  14. Dauerman HL. Reasonable incomplete revascularization. Circulation 2011; 123:2337.
  15. Kelbaek H, Thuesen L, Helqvist S, et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 2006; 47:449.
  16. Iakovou I, Ge L, Michev I, et al. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. J Am Coll Cardiol 2004; 44:967.
  17. Seung KB, Kim YH, Park DW, et al. Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J Am Coll Cardiol 2005; 46:787.
  18. Stone GW, Kandzari DE, Mehran R, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation 2005; 112:2364.
  19. Kahn JK. Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting. Am Heart J 1993; 126:561.
  20. Veen G, Meyer A, Verheugt FW, et al. Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis. J Am Coll Cardiol 1993; 22:1755.
  21. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.
  22. Stone GW, Reifart NJ, Moussa I, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation 2005; 112:2530.
  23. Kinoshita I, Katoh O, Nariyama J, et al. Coronary angioplasty of chronic total occlusions with bridging collateral vessels: immediate and follow-up outcome from a large single-center experience. J Am Coll Cardiol 1995; 26:409.
  24. Olivari Z, Rubartelli P, Piscione F, et al. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). J Am Coll Cardiol 2003; 41:1672.
  25. Surmely JF, Tsuchikane E, Katoh O, et al. New concept for CTO recanalization using controlled antegrade and retrograde subintimal tracking: the CART technique. J Invasive Cardiol 2006; 18:334.
  26. Galassi AR, Sianos G, Werner GS, et al. Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry. J Am Coll Cardiol 2015; 65:2388.
  27. George S, Cockburn J, Clayton TC, et al. Long-term follow-up of elective chronic total coronary occlusion angioplasty: analysis from the U.K. Central Cardiac Audit Database. J Am Coll Cardiol 2014; 64:235.
  28. Suero JA, Marso SP, Jones PG, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol 2001; 38:409.
  29. Hoye A, van Domburg RT, Sonnenschein K, Serruys PW. Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992-2002. Eur Heart J 2005; 26:2630.
  30. Baim DS, Kwong RY. Is magnetic resonance image guidance the key to opening chronic total occlusions? Circulation 2006; 113:1053.
  31. Agostoni P, Valgimigli M, Biondi-Zoccai GG, et al. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. Am Heart J 2006; 151:682.
  32. Buller CE, Dzavik V, Carere RG, et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation 1999; 100:236.
  33. Suttorp MJ, Laarman GJ, Rahel BM, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006; 114:921.
  34. Ge L, Iakovou I, Cosgrave J, et al. Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J 2005; 26:1056.
  35. Hoye A, Tanabe K, Lemos PA, et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol 2004; 43:1954.
  36. Werner GS, Krack A, Schwarz G, et al. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J Am Coll Cardiol 2004; 44:2301.
  37. Nakamura S, Muthusamy TS, Bae JH, et al. Impact of sirolimus-eluting stent on the outcome of patients with chronic total occlusions. Am J Cardiol 2005; 95:161.
  38. Powell BD, Rihal CS, Bell MR, et al. Anticipated impact of drug-eluting stents on referral patterns for coronary artery bypass graft surgery: a population-based angiographic analysis. Mayo Clin Proc 2004; 79:769.
  39. Bourassa MG, Roubin GS, Detre KM, et al. Bypass Angioplasty Revascularization Investigation: patient screening, selection, and recruitment. Am J Cardiol 1995; 75:3C.
  40. Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804.
  41. Kobayashi Y, De Gregorio J, Kobayashi N, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34:651.
  42. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109:1366.
  43. Wong SC, Hong MK, Ellis SG, et al. Influence of stent length to lesion length ratio on angiographic and clinical outcomes after implantation of bare metal and drug-eluting stents (the TAXUS-IV Study). Am J Cardiol 2005; 95:1043.
  44. Mauri L, O'Malley AJ, Popma JJ, et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2005; 95:1140.
  45. Tsagalou E, Chieffo A, Iakovou I, et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 2005; 45:1570.
  46. Degertekin M, Arampatzis CA, Lemos PA, et al. Very long sirolimus-eluting stent implantation for de novo coronary lesions. Am J Cardiol 2004; 93:826.
  47. Kereiakes DJ, Wang H, Popma JJ, et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol 2006; 48:21.
  48. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112:270.
  49. Aoki J, Ong AT, Rodriguez Granillo GA, et al. "Full metal jacket" (stented length > or =64 mm) using drug-eluting stents for de novo coronary artery lesions. Am Heart J 2005; 150:994.
  50. Williams DO, Abbott JD. Bifurcation intervention: is it crush time yet? J Am Coll Cardiol 2005; 46:621.
  51. Garot P, Lefèvre T, Savage M, et al. Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005; 46:606.
  52. Latib A, Colombo A. Bifurcation disease: what do we know, what should we do? JACC Cardiovasc Interv 2008; 1:218.
  53. Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol 2005; 46:1446.
  54. Al Suwaidi J, Berger PB, Rihal CS, et al. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J Am Coll Cardiol 2000; 35:929.
  55. Yamashita T, Nishida T, Adamian MG, et al. Bifurcation lesions: two stents versus one stent--immediate and follow-up results. J Am Coll Cardiol 2000; 35:1145.
  56. Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004; 109:1244.
  57. Steigen TK, Maeng M, Wiseth R, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 2006; 114:1955.
  58. Colombo A, Bramucci E, Saccà S, et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation 2009; 119:71.
  59. Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation 2010; 121:1235.
  60. Généreux P, Kumsars I, Lesiak M, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. J Am Coll Cardiol 2015; 65:533.
  61. Généreux P, Kumsars I, Schneider JE, et al. Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches: Outcomes From the Tryton Confirmatory Study. JACC Cardiovasc Interv 2016; 9:1338.
  62. Maeng M, Holm NR, Erglis A, et al. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. J Am Coll Cardiol 2013; 62:30.
  63. Koo BK, Kang HJ, Youn TJ, et al. Physiologic assessment of jailed side branch lesions using fractional flow reserve. J Am Coll Cardiol 2005; 46:633.
  64. Chen SL, Zhang JJ, Han Y, et al. Double Kissing Crush Versus Provisional Stenting for Left Main Distal Bifurcation Lesions: DKCRUSH-V Randomized Trial. J Am Coll Cardiol 2017; 70:2605.
  65. Niemelä M, Kervinen K, Erglis A, et al. Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. Circulation 2011; 123:79.
  66. Ge L, Airoldi F, Iakovou I, et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol 2005; 46:613.
  67. Costa RA, Mintz GS, Carlier SG, et al. Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis. J Am Coll Cardiol 2005; 46:599.
  68. Moussa I, Costa RA, Leon MB, et al. A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique". Am J Cardiol 2006; 97:1317.
  69. Agostoni P, Biondi-Zoccai GG, Gasparini GL, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J 2005; 26:881.
  70. Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362:1093.
  71. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004; 292:2727.
  72. Holmes DR Jr. Stenting small coronary arteries: works in progress. JAMA 2004; 292:2777.
  73. Menozzi A, Solinas E, Ortolani P, et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. Eur Heart J 2009; 30:2095.
  74. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294:1215.
  75. Elezi S, Dibra A, Mehilli J, et al. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006; 48:1304.
  76. Mehilli J, Dibra A, Kastrati A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006; 27:260.
  77. Togni M, Eber S, Widmer J, et al. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 2007; 50:1123.
  78. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.
  79. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221.
  80. Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J 2000; 21:1739.
  81. Steinberg DH, Mishra S, Javaid A, et al. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (> or =3.5 mm) coronary arteries. Am J Cardiol 2007; 99:599.
  82. Brunner-La Rocca HP, Kaiser C, Pfisterer M, BASKET Investigators. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007; 28:719.
  83. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, et al. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 2009; 30:16.
  84. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007; 357:1393.
  85. Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363:2310.